PHASE IB STUDY OF LENVATINIB (E7080) IN COMBINATION WITH TEMOZOLOMIDE FOR TREATMENT OF ADVANCED MELANOMA
Phase IB Study of Lenvatinib (E7080) in Combination With Temozolomide for Treatment of Advanced Melanoma.
Archive for Publications
SHEDDING NEW LIGHT ON THE USE OF IMAGING TECHNOLOGY FOR GLIOBLASTOMA TUMOR RESECTION
Shedding New Light on the Use of Imaging Technology for Glioblastoma Tumor Resection.
CLINICAL PHARMACOLOGY CHARACTERIZATION OF RG7112, AN MDM2 ANTAGONIST, IN PATIENTS WITH ADVANCED SOLID TUMORS
Clinical pharmacology characterization of RG7112, an MDM2 antagonist, in patients with advanced solid tumors.
RELATIONSHIPS OF CLINICAL RESPONSE TO RELEVANT MOLECULAR SIGNAL DURING PHASE I TESTING OF AURORA KINASE A INHIBITOR: RETROSPECTIVE ASSESSMENT
Relationships of Clinical Response to Relevant Molecular Signal During Phase I Testing of Aurora Kinase A Inhibitor: Retrospective Assessment.
SURVIVIN-TARGETED IMMUNOTHERAPY DRIVES ROBUST POLYFUNCTIONAL T CELL GENERATION AND DIFFERENTIATION IN ADVANCED OVARIAN CANCER PATIENTS
Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.
PHASE I TRIAL OF BI-SHRNA STMN1 BIV IN REFACTORY CANCER
Phase I Trial of bi-shRNA STMN1 BIV in Refactory Cancer. Molecular Therapy 2015 Jun;23(6):1123-30.
LIPOSOMAL INSULIN PROMOTERTHYMIDINE KINASE GENE THERAPY FOLLOWED BY GANCICLOVIR EFFECTIVELY ABLATES HUMAN PANCREATIC CANCER IN MICE
Liposomal insulin promoter-thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice. Cancer Lett. 2015 Apr 10;359(2):206-10.
Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma.
A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer.
PILOT TRIAL OF (FANG™) IMMUNOTHERAPY IN EWING’S SARCOMA
Pilot Trial of FANG™ Immunotherapy in Ewing’s Sarcoma. Molecular Therapy 2015 Jun;23(6):1103-9.
AZD9150, A NEXT-GENERATION ANTISENSE OLIGONUCLEOTIDE INHIBITOR OF STAT3, WITH EARLY EVIDENCE OF CLINICAL ACTIVITY IN LYMPHOMA AND LUNG CANCER
Next-Generation Antisense Oligonucleotide Inhibitor of STAT3, with Early Evidence of Clinical Activity in Lymphoma and Lung Cancer. Science Translational Medicine 2015 Nov 18;7(314):314ra185.